Targeting the Hedgehog Pathway in Cancer: Current Evidence and Future Perspectives
AbstractThe Hedgehog pathway (HhP) plays an important role in normal embryonic development and its abnormal function has been linked to a variety of neoplasms. Recently, the complex mechanisms involved in this pathway have been deciphered and the cross talks with other important pathways involved in carcinogenesis have been characterized. This knowledge has led to the development of targeted therapies against key components of HhP, which culminated in the approval of vismodegib for the treatment of advanced basal cell carcinoma in 2012. Since then, other compounds have been developed and evaluated in preclinical and clinical studies with interesting results. Today, several medications against components of the HhP have demonstrated clinical activity as monotherapies and in combination with cytotoxic treatment or other targeted therapies against mitogenic pathways that are linked to the HhP. This review aims to clarify the mechanism of the HhP and the complex crosstalk with others pathways involved in carcinogenesis and to discuss both the evidence associated with the growing number of medications and combined therapies addressing this pathway and future perspectives. View Full-Text
Share & Cite This Article
Girardi, D.; Barrichello, A.; Fernandes, G.; Pereira, A. Targeting the Hedgehog Pathway in Cancer: Current Evidence and Future Perspectives. Cells 2019, 8, 153.
Girardi D, Barrichello A, Fernandes G, Pereira A. Targeting the Hedgehog Pathway in Cancer: Current Evidence and Future Perspectives. Cells. 2019; 8(2):153.Chicago/Turabian Style
Girardi, Daniel; Barrichello, Adriana; Fernandes, Gustavo; Pereira, Allan. 2019. "Targeting the Hedgehog Pathway in Cancer: Current Evidence and Future Perspectives." Cells 8, no. 2: 153.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.